Top Markets
Coin of the day
D. Western Therapeutics Institute, Inc. D. Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute, Inc.

4576
Kedudukan dalam Saham #27476
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused... D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
Harga Saham
$0.57414457
Modal Pasaran
$33.00M
Perubahan (1 hari)
4.76%
Perubahan (1 tahun)
-23.09%
Negara
JP
Perdagangan D. Western Therapeutics Institute, Inc. (4576)

Kategori

Nisbah P/S bagi D. Western Therapeutics Institute, Inc. (4576)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini D. Western Therapeutics Institute, Inc., nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk D. Western Therapeutics Institute, Inc. dari 2026 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH